Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TC vs TAC with bevacizumab-containing TCB in adjuvant HER2-negative breast cancer
2010-021587-15Phase 3Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Jul 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, cyclophosphamide, doxorubicin and docetaxel in breast cancer (3 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Invasive disease-free survival. Started Jul 2010; status: completed.
02
Drugs
bevacizumabcyclophosphamidedoxorubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-021587-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021587-15.